The massive revenue growth and positive free cash flow inflection are strong fundamental signals, but the large EPS miss and revenue shortfall vs consensus introduce skepticism. Monitor next quarter's actual IM8 revenue vs the $400M+ FY2027 target and whether consolidated ACF remains positive. The webcast and detailed Shareholder Letter may provide cohort economics that either confirm or challenge the growth narrative.
Price Chart
Executive Summary
Prenetics Q2 2026 revenue surged ~288% YoY to $46.5M, driven by its IM8 brand ($45M, 359% YoY), but GAAP EPS of -$1.61 missed consensus of -$0.48 by 235%. The company raised FY2026 total revenue guidance to $220-230M and initiated FY2027 IM8 revenue guidance of $400M+ while achieving its first quarter of positive consolidated adjusted free cash flow.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $46.5M, ~288% YoY growth, within guidance of $46-48M
- IM8 brand revenue $45.0M, ~359% YoY, within guidance of $44-46M, sixth consecutive record quarter
- July 2026 IM8 revenue $20.9M = $251M annualized run-rate
- Raised FY2026 total revenue guidance to $220-230M
- Initiated FY2027 IM8 revenue guidance of $400M+ with no new product launches assumed
- First quarter of positive consolidated Adjusted Free Cash Flow, expected to remain positive
- GAAP EPS -$1.61 missed consensus of -$0.48; surprise -235.4%
- Revenue of $46.5M missed consensus of $49.2M by -5.5%
Financial Impact
Revenue growing ~4x YoY to $251M annualized run-rate; guidance implies ~$220-230M FY2026 total revenue, $400M+ IM8 revenue target for FY2027
Risk Factors
- GAAP EPS miss of -235% vs consensus signals significant costs or dilution
- Revenue of $46.5M missed $49.2M consensus by 5.5%
- FY2027 guidance of $400M+ assumes no new products and may be aggressive
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3346717 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $21.27 | awaiting T+60 | — | $18.37 (−13.63%) |
Sep 22, 2026 4w ago | F-1/A | $22.90 | awaiting T+60 | — | $18.37 (−19.78%) |
Aug 26, 2026 8w ago | 6-K | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | Insider Cluster | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | 3 | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 20, 2026 9w ago | 6-K | $17.97 | awaiting T+60 | — | $18.37 (+2.23%) |
Aug 18, 2026 9w ago | 6-K | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 18, 2026 9w ago | Press Release | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 17, 2026 10w ago | 6-K | $19.37 | awaiting T+60 | — | $18.37 (−5.16%) |
Aug 7, 2026 11w ago | F-1/A | $18.26 | awaiting T+60 | — | $18.37 (+0.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers